Center for Epidemiologic Studies Depression Scale

Talc Victims to Johnson & Johnson: There’s No Escaping Science Linking Talc with Ovarian Cancer and Mesothelioma

Retrieved on: 
Mercredi, juin 7, 2023
Legal, Women, Other Retail, Professional Services, Health, Consumer, General Health, Retail, Oncology, Credible, Talc, Carcinogen, Cancer, Center for Epidemiologic Studies Depression Scale, Woman, Lawyer, Inflammation, United States Court of Appeals for the Third Circuit, Government, Science, J&J, MDL, Congress, Risk, Asbestos, Johnson & Johnson, Ovarian cancer, Bankruptcy, Birth control

Studies in women consistently demonstrate that genital use of talcum powder increases the risk of and can cause ovarian cancer.

Key Points: 
  • Studies in women consistently demonstrate that genital use of talcum powder increases the risk of and can cause ovarian cancer.
  • Credible scientific studies demonstrate that talcum powder causes inflammation, and that chronic inflammation causes ovarian cancer.
  • Since the 1980s, more than 40 published epidemiologic studies have examined the link between genital talc use by women and ovarian cancer and have documented significant links between the two.
  • In June 2021 Johnson & Johnson paid 22 cancer victims and their families more than $213 million each.

New Study finds Volumetric Absorptive Micro-Samplers (VAMS) Prove to be Useful Self-Collection Tools for Assessing Human Exposure to PFAS

Retrieved on: 
Mardi, mai 16, 2023
Other Consumer, Environment, Sustainability, Green Technology, Other Natural Resources, Health, Consumer, General Health, Natural Resources, Duke University, Human, PFAS, Serum, Center for Epidemiologic Studies Depression Scale, Plasma, Volume, Colorado School of Mines, Blood, Michigan State University, Biophysical environment, Per- and polyfluoroalkyl substances, American Chemical Society, Cosmetics

This method effectively quantifies PFAS in whole blood samples collected by volumetric micro samplers (VAMS).

Key Points: 
  • This method effectively quantifies PFAS in whole blood samples collected by volumetric micro samplers (VAMS).
  • PFAS, short for per- and polyfluoroalkyl substances, are a class of very stable compounds with unique characteristics making them largely unsusceptible to degradation.
  • Recent studies have indicated whole blood, collected easily with VAMS, to be a better approach for assessing exposure to a broader suite of PFAS.
  • PFAS levels in serum were highly correlated with measurements in capillary VAMS, indicating that VAMS are useful self-collection tools for assessing human exposure to PFAS.

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

Retrieved on: 
Mardi, janvier 17, 2023
Associate, Roche, Center for Epidemiologic Studies Depression Scale, MS, Genetic counseling, Molecular epidemiology, Pancreatic cancer, Medical Affairs Bureau, Economics, Ohio State University, Diagnosis, Survival, Genomics, Engineering, Roche Diagnostics, Cancer, Doctor of Philosophy, Pharmaceutical industry, Genetics, Genetic

Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.

Key Points: 
  • Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.
  • Prior to joining Roche, she spent over 13 years in academia, most recently as a tenured Associate Professor at The Ohio State University.
  • Her lab focused on the contribution of genomics to cancer susceptibility and survival following diagnosis.
  • Lara brings expertise in designing, implementing, analyzing, and leading large-scale international clinical, biomarker, genomic and epidemiologic studies resulting in national and international scientific presentations and over 130 peer-reviewed publications.

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

Retrieved on: 
Mardi, janvier 17, 2023
Associate, Roche, Center for Epidemiologic Studies Depression Scale, MS, Genetic counseling, Molecular epidemiology, Pancreatic cancer, Medical Affairs Bureau, Economics, Ohio State University, Diagnosis, Survival, Genomics, Engineering, Roche Diagnostics, Cancer, Doctor of Philosophy, Pharmaceutical industry, Genetics, Genetic

Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.

Key Points: 
  • Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.
  • Prior to joining Roche, she spent over 13 years in academia, most recently as a tenured Associate Professor at The Ohio State University.
  • Her lab focused on the contribution of genomics to cancer susceptibility and survival following diagnosis.
  • Lara brings expertise in designing, implementing, analyzing, and leading large-scale international clinical, biomarker, genomic and epidemiologic studies resulting in national and international scientific presentations and over 130 peer-reviewed publications.

Largest decentralised study of its kind shows high levels of engagement with Huma's study app

Retrieved on: 
Vendredi, janvier 13, 2023
Ageing, University, Center for Epidemiologic Studies Depression Scale, Checklist, Therapy, Temperature, COVID-19, Medicine, Biomarker, Health, Huma, Data collection, Patient, Diet, Journal, Observational study, Research, Clinical trial, Android, IPhone, Pharmaceutical industry, Vaccine

In addition to using the study app (available for both iPhone and Android), each was also sent a digital pulse oximeter (to measure blood oxygen levels) and thermometer.

Key Points: 
  • In addition to using the study app (available for both iPhone and Android), each was also sent a digital pulse oximeter (to measure blood oxygen levels) and thermometer.
  • Participants had a positive experience with the study app, finding it easy to use and quick to report measurements and symptoms.
  • On average, people used the study app for 34.5 weeks (7.9 months), with only 2.5% of participants withdrawing from the study.
  • The high level of engagement and retention we've seen in this study is very encouraging.

Largest decentralised study of its kind shows high levels of engagement with Huma's study app

Retrieved on: 
Vendredi, janvier 13, 2023
Ageing, University, Center for Epidemiologic Studies Depression Scale, Checklist, Therapy, Temperature, COVID-19, Medicine, Biomarker, Health, Huma, Data collection, Patient, Diet, Journal, Observational study, Research, Clinical trial, Android, IPhone, Pharmaceutical industry, Vaccine

In addition to using the study app (available for both iPhone and Android), each was also sent a digital pulse oximeter (to measure blood oxygen levels) and thermometer.

Key Points: 
  • In addition to using the study app (available for both iPhone and Android), each was also sent a digital pulse oximeter (to measure blood oxygen levels) and thermometer.
  • Participants had a positive experience with the study app, finding it easy to use and quick to report measurements and symptoms.
  • On average, people used the study app for 34.5 weeks (7.9 months), with only 2.5% of participants withdrawing from the study.
  • The high level of engagement and retention we've seen in this study is very encouraging.

C2N Diagnostics Introduces the PrecivityAD2™ Blood Test

Retrieved on: 
Mardi, novembre 29, 2022
Mental Health, Health, Neurology, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pathology, Doctor of Philosophy, Amyloid, Dementia, Approximation error, Diagnosis, Altruism, Peptide, PET, Apolipoprotein, Senior Consultant, Washington University School of Medicine, Health, AD, Patient, Lund University, Clinical trial, Ageing, Biomarker, Neurodegeneration, Radiation, BrightFocus Foundation, Disease, MD, Government budget balance, Research, Center for Epidemiologic Studies Depression Scale, Benefit, Cerebrospinal fluid, Apolipoprotein E, CSF, Plasma, Genotype, EU, APS2, Medical imaging, C2N, Neurology

C2N Diagnostics , LLC (C2N), a leader in advanced brain health diagnostics, today announced at the Clinical Trials on Alzheimers Disease (CTAD) 2022 EU/US Task Force on Blood Biomarkers its next generation test to aid in the diagnosis of Alzheimers disease (AD): the PrecivityAD2 blood test.

Key Points: 
  • C2N Diagnostics , LLC (C2N), a leader in advanced brain health diagnostics, today announced at the Clinical Trials on Alzheimers Disease (CTAD) 2022 EU/US Task Force on Blood Biomarkers its next generation test to aid in the diagnosis of Alzheimers disease (AD): the PrecivityAD2 blood test.
  • The PrecivityAD2 blood test is a significant innovation in the field of Alzheimers diagnostics.
  • The PrecivityAD2 test is our next-generation blood test, a natural extension of our prior two years of clinical experience with the PrecivityAD test.
  • C2N looks forward to sharing additional clinical data and details of the upcoming commercial launch of the PrecivityAD2 blood test as a validated laboratory developed test from our CLIA-certified and CAP-accredited laboratory in early 2023.

International Researchers Poised to Learn New Insights About C2N Diagnostics’ Blood Test Innovations at Clinical Trials on Alzheimer’s Disease Conference

Retrieved on: 
Jeudi, novembre 17, 2022
Research, Seniors, Neurology, Clinical Trials, Biometrics, Biotechnology, Pharmaceutical, Consumer, Health, Science, AD, AFL, Washington University School of Medicine, Health, Clinical trial, Biomarker, Diagnosis, Center for Epidemiologic Studies Depression Scale, Neurodegeneration, Alzheimer's disease, Disease, Rapunzel's Tangled Adventure (season 2), CSF, Neurology, Plasma, Medical imaging, Soft drink

C2N Diagnostics , a leader in advanced brain health diagnostics, will offer multiple presentations and posters to highlight new, important insights relating to its PrecivityAD blood test, p-tau MAA and other unique biomarkers that aid healthcare providers in diagnosing Alzheimers disease at the Clinical Trials on Alzheimer's Disease (CTAD) conference.

Key Points: 
  • C2N Diagnostics , a leader in advanced brain health diagnostics, will offer multiple presentations and posters to highlight new, important insights relating to its PrecivityAD blood test, p-tau MAA and other unique biomarkers that aid healthcare providers in diagnosing Alzheimers disease at the Clinical Trials on Alzheimer's Disease (CTAD) conference.
  • Of high interest will be multiple late-breaker oral presentations regarding C2N innovations, including CEO Dr. Joel B. Braunsteins on December 2.
  • During the presentation he will share new data about the clinical diagnostic usefulness of the PrecivityAD test and its impact on medical decision-making among practicing neurologists.
  • CN strives to provide exceptional laboratory services and products in the field of brain health.

C₂N Diagnostics Marks Two Years of PrecivityAD® Blood Test Accomplishments

Retrieved on: 
Vendredi, octobre 21, 2022
Research, General Health, Biometrics, Consumer, Mental Health, Genetics, Clinical Trials, Science, Neurology, Biotechnology, Seniors, Health, Other Science, Fillit, CAP, ISO, Health, Union, Time, AARP, Memory, Randall, CE marking, Amnesia, Accreditation, Disease, Efficiency, Conference, Diagnosis, Accreditation Committee of Cambodia, Molecular Neurodegeneration, COVID, JAMA Network Open, Cognition, List of American Medical Association journals, Patient, Center for Epidemiologic Studies Depression Scale, Research, Alzheimer's disease, Entrepreneurship, Clarity, Dementia, Technology, Automation, Certification, Clinica Chimica Acta, Washington University in St. Louis, Trial of the century, Davos, Magazine, LC-MS/MS, College, American Medical Association, News, Clinical trial, PET, Eisai, NBC News, Biogen, Neurodegeneration, Medical device, Medical imaging, Pharmaceutical industry, Brain

The company boldly launched the PrecivityAD blood test during the height of the COVID pandemic in October 2020.

Key Points: 
  • The company boldly launched the PrecivityAD blood test during the height of the COVID pandemic in October 2020.
  • Molecular Neurodegeneration was the first to distribute a research paper that stated the PrecivityAD blood test can accurately identify brain amyloid status based on a single blood sample.
  • AARP The Magazine reported on Shelby Hileman, who also received an Alzheimers diagnosis after her doctor reviewed her PrecivityAD blood test result.
  • In a TV story , a wife shared why her husband decided to take the PrecivityAD blood test after his doctor recommended it.

Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

Retrieved on: 
Lundi, octobre 3, 2022
Area studies, Ponce Health Sciences University, Degenerative disease, Tuberculosis, Science, U.S. Securities and Exchange Commission, Adult, Physician, Center for Epidemiologic Studies Depression Scale, Nasdaq, Research, Infection, Pyelonephritis, NTM, Rheumatology, Mentorship, FDA, MPH, HBR, MDR, Tebipenem, Q&A, Public health, Oregon Health and Science University Center for Women's Health, Bacteria, Therapy, Cutis verticis gyrata, Oregon Health & Science University, Bronchiectasis, OHSU, Patient, Division, Center, Publication, Universal Music Publishing Group, GLOBE, Ophthalmology, Pharmaceutical industry, Spero, MD

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a virtual R&D event on Thursday, October 6, 2022, at 11:30 a.m. Eastern Time.

Key Points: 
  • The virtual event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH, from the Division of Infectious Disease, OHSU Medical School.
  • During his presentation, Dr. Winthrop will discuss the etiology, unmet medical need, and treatment landscape of non-tuberculous mycobacteria (NTM) pulmonary disease.
  • Members of the Spero management team will provide an overview of the development program for SPR720, a potential novel first line oral therapy for NTM infections.
  • Spero Therapeuticsis developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.